Caribou Biosciences reports Q2 EPS (35c), one estimate (42c)

Reports Q2 revenue $2.7M, consensus $1.64M. The company had $183.9M in cash, cash equivalents, and marketable securities as of June 30, which it expects will be sufficient to fund its current operating plan into H2 2027. “Caribou is advancing allogeneic CAR-T cell programs to deliver off-the-shelf therapies designed for rapid treatment and broad patient access,” said Rachel Haurwitz, Caribou’s president and CEO. “Our clinical programs, CB-010 for large B cell lymphoma and CB-011 for multiple myeloma, continue to generate encouraging Phase 1 results, reinforcing our conviction in the potential of these therapies. We remain on track to report robust datasets from both programs this year, which we expect to provide meaningful insights into the potential of our approach and the future of allogeneic CAR-T cell therapies.”